# The Efficacy and Safety of Treatment with Telitacicept in Antineutrophil Cytoplasmic Antibody-associated Nephritis (AAGN)

> **NCT06656962** · PHASE1,PHASE2 · ACTIVE_NOT_RECRUITING · sponsor: **Renmin Hospital of Wuhan University** · enrollment: 15 (actual)

## Conditions studied

- Antineutrophil Cytoplasmic Antibody (ANCA)-associated Nephritis (AAGN)

## Interventions

- **DRUG:** Telitacicept 160mg
- **DRUG:** Prednisone (and methylprednisolone)
- **DRUG:** Cyclophosphamide

## Key facts

- **NCT ID:** NCT06656962
- **Lead sponsor:** Renmin Hospital of Wuhan University
- **Sponsor class:** OTHER
- **Phase:** PHASE1,PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** ACTIVE_NOT_RECRUITING
- **Start date:** 2024-10-10
- **Primary completion:** 2025-12-30
- **Final completion:** 2026-10-30
- **Target enrollment:** 15 (ACTUAL)
- **Last updated:** 2024-10-24


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT06656962

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT06656962, "The Efficacy and Safety of Treatment with Telitacicept in Antineutrophil Cytoplasmic Antibody-associated Nephritis (AAGN)". Retrieved via AI Analytics 2026-06-02 from https://api.ai-analytics.org/clinical/NCT06656962. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*